Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP3
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AP3 is a GPR40 AgoPAM (Agonist/Positive Allosteric Modulator) small molecule developed by Merck & Co., Inc. as a potential oral antidiabetic therapeutic for type 2 diabetes. It functions by stimulating both insulin and incretin (GLP-1, GIP, PYY) secretion, leading to glucose lowering and body weight reduction. Uniquely, AP3 also causes a significant and sustained increase in glucagon secretion, a target-mediated effect requiring the GPR40 receptor. Its mechanism involves both direct stimulation of beta cells and indirect effects through GLP-1 secretion, contributing to enhanced glucose-dependent insulin secretion.
02
Targets
FFAR1 (Free fatty acid receptor 1)
Beyond the preview
Go deeper on AP3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP3.